Page 3 - ஏறிக் பென்சர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lower sales due to the pandemic but new rights issue secures continued international expansion First quarter Result after tax came in at SEK -8.9 (0.7) million. Earnings per share, basic and diluted, were SEK -0.06 (0.01). Cash and cash equivalents were SEK 21.4 (33.9) million. Significant events in Q1 Enzymatica s sales during the quarter declined compared with the corresponding period in 2020 due to the effects of the pandemic, which essentially reduced the cold remedy market by 50 percent, both in Sweden and in other markets. Enzymatica announced on March 22 that sales for 2021 could be lower than sales for 2020, which totaled SEK 111 million, because of the impact of the pandemic on the cold remedy market. The Board of Directors has therefore decided to raise SEK 59 million through a rights issue to fund the company s long-term initiatives and to meet working capital needs for the next 12 months.

United kingdomCzech republicBengt baronMalin richterKostenloser wertpapierhandelKristoffer ahlerupTherese filmerssonErik penser bankDirector operationsDirector commercialAnnual general meetingExecutive chairmanNasdaq first north growth marketIdeon science parkNasdaq first north growthErik penser